|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2002-10-18
|
|
pubmed:abstractText |
Combination therapy of ribavirin with interferon alfa-2b and pegylated interferon alfa-2b is currently approved for the treatment of chronic hepatitis C. Approved ribavirin dosages vary from a fixed dosage of 800 mg/d to as much as 1200 mg/d on the basis of body weight.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
349-61
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12386637-Adult,
pubmed-meshheading:12386637-Aged,
pubmed-meshheading:12386637-Confidence Intervals,
pubmed-meshheading:12386637-Dose-Response Relationship, Drug,
pubmed-meshheading:12386637-Female,
pubmed-meshheading:12386637-Hepatitis C, Chronic,
pubmed-meshheading:12386637-Humans,
pubmed-meshheading:12386637-Logistic Models,
pubmed-meshheading:12386637-Male,
pubmed-meshheading:12386637-Models, Biological,
pubmed-meshheading:12386637-Ribavirin
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models.
|
|
pubmed:affiliation |
Department of Statistics, Schering-Plough Research Institute, Kenilworth, NJ, USA. frank.jen@pharma.novartis.com
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Validation Studies
|
